When Should Change Applications Be Submitted for Overseas Registration of Dental Devices?

Not all changes to a registered dental device require a formal submission to regulatory authorities. However, determining which changes must be reported is critical for maintaining certificate validity, regulatory compliance, and market access eligibility. Companies should evaluate whether a change affects product safety or basic design, touches on information recorded in the registration certificate, or alters key elements such as intended use, working principle, materials, sterilization method, packaging, or manufacturing site. If a reportable change is identified, it must be submitted according to the target country’s change classification (e.g., notification, filing, prior approval, or annual update). Even administrative information changes that do not affect safety must be communicated and the registration information updated. In addition, companies must demonstrate that the product before and after the change still meets the standards and clinical evaluation requirements on which the original registration was based, supplementing with biological evaluation, performance verification, risk management analysis, or clinical evidence as necessary. This article provides a comprehensive guide to the decision logic, documentation, common pitfalls, and multi-country considerations for dental device registration changes.

Executive Summary

Not all changes to a registered dental device require a formal submission to regulatory authorities, but the judgment criteria directly affect certificate validity, compliance status, and market access. Companies must first confirm whether the change affects product safety and basic design, touches on information on the registration certificate, or changes intended use, working principle, materials, sterilization method, packaging, or production site. If so, the change must be submitted according to the target country’s regulatory change types (notification, filing, prior approval, annual update). If it is determined to be an administrative information change not affecting safety, timely communication and updating of registration information are still required. At the same time, companies must prove that the product after the change still satisfies the standards and clinical evaluation requirements on which the original registration was based, supplementing biological evaluation, performance verification, risk management analysis, and clinical evidence as necessary. In multi-country registration scenarios involving GHWP member countries, Southeast Asia, the Middle East, and Latin America, change submissions should be based on core technical file reuse and localized conversion for different countries’ change classifications and local agent requirements. The most common problems are neglecting the impact of changes on post-market surveillance systems or failing to retain complete change records, which prevents passing regulatory review. Companies should plan before initiating changes, confirming the scope of updates to technical documents, quality systems, labeling, and registration certificate attachments, to avoid product suspension or certificate revocation caused by delayed change submissions.

Applicable Scenarios and Core Questions

After a dental device obtains overseas registration, companies often face product adjustments, process optimization, or production transfers. The most pressing question is: which changes require notification, which can be handled internally, and which can be deferred until certificate renewal? Without a clear boundary, companies may fall into two extremes: treating every minor modification as a major change, leading to unnecessary corrections and marketing suspension risks, or ignoring critical changes until the certificate is suspended or revoked.

Submitting a change notification is not simply telling the regulator that “we have changed”; it requires proving that the product after the change still meets the safety and performance requirements on which the original registration was based. For dental devices, common changes include: material composition adjustments, surface treatment changes, changes in adhesives or curing lights, sterilization method changes, packaging system replacements, expansion or narrowing of intended use, adjustments to tooth positions or patient populations, and substantial changes to manufacturing sites or processes. Even if a change is eligible for annual aggregated reporting in the country of original registration, another GHWP member country or target market may require prior approval.

Therefore, the core judgment cannot rely solely on whether the change is “big” or “small.” It must also consider how the target country’s regulations classify changes, whether information on the original registration certificate is affected, and whether the change undermines the completeness of safety and performance verification. Companies should establish a systematic change assessment process, initiating an overseas registration impact analysis at the change planning stage, rather than retroactively determining how to submit after the change has been implemented.

Regulatory Decision Logic

To determine whether an overseas registration change for a dental device must be submitted, a three-tier analysis should be applied.

Tier 1: Confirm Regulatory Scope and Registration Validity

First, confirm whether the target country regulates the dental device as a medical device and whether the current registration certificate is still valid. If the product is outside the regulatory scope or has been deregistered, the obligation to submit changes differs. However, other regulations such as consumer protection or biocompatibility requirements may still apply.

Tier 2: Assess Impact on Registration and Technical Files

Second, evaluate whether the change touches critical parts of the registration certificate, technical documentation, or quality system. Specifically, examine five dimensions:

• Product name and model
• Intended use, indications, or contraindications
• Device design principle, working principle, or critical components
• Materials, chemical composition, or media in contact with the human body
• Sterilization method, packaging, or shelf life

A substantive change in any dimension typically constitutes a notifiable change. However, classification differs by country: some require prior approval, others allow notification before marketing, and others require aggregated reporting in annual updates.

Tier 3: Consider Reusability of Existing Documentation

Third, consider the reusability of existing data. If the company has experience with NMPA registration changes, CE technical files, FDA 510(k) change records, or ISO 13485 change records, these should be analyzed for gaps. For example, if a dental implant system added a new surface treatment process in an NMPA change, the physical/chemical performance, biocompatibility, and stability verification data may be reused when applying for a change in a GHWP member country. However, the clinical evaluation must be reassessed to confirm whether it covers the long-term osseointegration performance of the new process. Similarly, if a dental resin material changed its initiator system in a CE filing without altering clinical indications, a new cytotoxicity test report may still be required in Southeast Asian countries because local requirements for monomer residues differ.

Finally, companies must confirm whether the local agent, authorized representative, or registrant has the obligation to submit change notifications, and who holds control of the certificate. If the original registration certificate is held by an importer, the importer leads the change submission, but the company must provide full technical support. If the company is the overseas registrant, it must appoint a local agent in the target country and ensure that the registrant, agent, and manufacturing site information are synchronized.

Documentation and Evidence

Change notification submissions must generally include complete evidence demonstrating equivalence or acceptable differences before and after the change. Companies should prepare four core documentation types:

• Change description and rationale
• Updated technical file records
• Verification and validation data
• Revised labeling and instructions for use

For dental devices, typical evidence includes:

• Biological evaluation reports (e.g., ISO 10993 series)
• Mechanical performance tests
• Corrosion resistance tests
• Fatigue tests
• Bond strength or sealing validation
• Sterilization validation
• Shelf-life studies

If the change involves intended use, such as extending from single-tooth restoration to multi-unit bridge restoration, sufficient clinical evaluation or clinical evidence must be provided. For material composition changes, update the material safety data sheet, chemical composition analysis, toxicological risk assessment, and biocompatibility evaluation. For sterilization method changes, such as from ethylene oxide to irradiation, re-validate the sterilization process, packaging integrity, and residue testing. For manufacturing site changes, provide evidence of the new site’s quality system certification (e.g., ISO 13485 or MDSAP certificate) and describe the transfer of process validation and process confirmation.

In a multi-country registration scenario, establish a two-tier file structure: a “core technical file package” and a “country-specific difference file package.” The core package contains common data on product design and verification that can be reused across countries; the country-specific package addresses local regulatory formats, language requirements, clinical data acceptance standards, and local agent documentation. When a change occurs, only the affected sections of the core package need to be updated, and then assembled according to each country’s requirements, rather than regenerating the entire set of files.

In addition, labels and instructions for use before and after the change must be updated simultaneously, with revision history and version numbers retained. During regulatory inspections, consistency between labels/instructions and the approved change content is a key focus. If a company updates only the technical file but forgets to update the commercial packaging labels, it may be deemed non-compliant.

Common Mistakes

• Confusing the “change record” in internal development files with the “change application” in regulatory submissions, assuming internal approval is sufficient and ignoring overseas registration obligations.
• Combining multiple changes into a single submission to save time without explaining the independent impact and validation data of each change, leaving regulators unable to assess risk.
• Focusing only on product changes while overlooking the impact of supply chain changes—such as manufacturing address, sterilization site, or key supplier changes—on the registration certificate.
• Continuing to sell products after receiving a deficiency notice for a change submission, without supplementing the required information, resulting in the product being considered an unauthorized change.
• Over-relying on CE or FDA change conclusions and assuming that GHWP member countries and Southeast Asian markets automatically accept changes allowed in Europe or the U.S., ignoring local independent requirements for clinical evidence.
• Failing to verify whether the local agent has change submission experience, or failing to complete the handover before an agent change, leading to certificate invalidation or delayed submissions.
• Not retaining samples, original validation data, and test reports before and after the change, making it impossible to demonstrate compliance during official inspections.
• Continuing production and shipment according to the old technical file during the submission period, resulting in actual products inconsistent with the registered information.

Preparedness Checklist for Companies

• Establish a cross-functional change review team including registration, R&D, quality, production, marketing, and sales representatives, clearly defining responsibilities for change initiation and assessment.
• At the change planning stage, compile a list of target country regulations, confirming each country’s change classification and submission deadlines.
• Review the original registration certificate attachments, technical file summaries, and label filings to identify all items that may be triggered by the change.
• Conduct a gap analysis to determine which existing NMPA, CE, FDA, MDSAP, or other market documentation can be reused and which must be regenerated.
• Determine whether clinical evaluation or clinical evidence updates are needed, and discuss with clinical experts and local agents as early as possible.
• Update quality system documentation to ensure design change records, risk management files, and validation reports are traceable.
• Sign change submission service agreements with local agents, clarifying responsibilities, timelines, and fees for both parties.
• Develop a synchronized update plan for labels and instructions for use to avoid wasting old-version label inventory.
• For multi-country registration projects, establish a change submission priority and coordination timeline to avoid conflicting deficiency responses across countries.
• Retain change application receipts, approval documents, and submission records in the post-market surveillance files.

AIMEILI's Interpretation

The most common misjudgment in overseas registration changes for dental devices is equating “technically recognized” with “regulatory compliant.” R&D departments may assume that internal validation is sufficient, but the essence of an overseas registration change is answering “can this still be marketed under the original approval conditions?” rather than “is this product safe?”

Companies should perform a registration impact assessment at the project planning stage, not after the product has been changed. We recommend that the registration team be involved before the R&D plan is finalized, to determine the change type and potentially affected countries. Early assessment can prevent costly rework and time delays that occur if submission is only addressed after molds have been made and production lines built.

Which data can be reused and which must be localized? Objective data such as physical/chemical tests, biocompatibility tests, and fatigue tests are often reusable across countries, but clinical evaluation acceptance criteria, biocompatibility comparison standards, sterilization residue limits, and label language and warnings differ. Companies should not simply translate English labels into local languages; they must verify local regulations on warning statements, units, and material composition labeling.

Local agents, certificate control, and change/renewal coordination are the three levers of an overseas registration system. Companies should treat local agents as regulatory partners, not document transmitters. Certificate control must be clear, especially when the original registration is held by a distributor; the decision-making power for change submissions may not be controllable. Renewal and change submissions should be planned together to avoid a single change disrupting the existing renewal cycle.

For multi-country registration, the key to reducing redundant compilation and deficiency risks is to build an updatable “change impact matrix.” List all target countries’ change classifications, documentation requirements, deadlines, and agent responsibilities in one table. When a change occurs, quickly identify which countries require prior approval, which require notification, and which can use aggregated reporting. This ensures compliance and enhances submission efficiency.

Frequently Asked Questions

If we only change the color of the packaging box for a dental device, do we need to submit a change notification?

If the packaging color change does not affect label content, warning information, expiration date labeling, or device identification symbols, it typically does not constitute a substantive change and does not require a submission to regulatory authorities. However, if the new packaging leads to increased residual sterilant gas or affects the sterile barrier performance of the product, you must re-validate the packaging and submit a change record.

If a change submission is rejected, can we continue to sell the original product?

If regulatory authorities determine that the changed product has been marketed without approval, they typically issue a suspension or prohibition notice. You should immediately stop selling the affected batches and discuss an appeal plan with your local agent. If the change submission itself is rejected, analyze whether the cause is insufficient evidence or an incorrect submission pathway, correct it, and resubmit—do not rely on luck.

Do other GHWP member countries always require local clinical data?

Requirements vary significantly by country. Some member countries accept literature reviews and equivalence arguments based on overseas clinical data, while others require clinical evaluation summaries or clinical trial summaries from the local population. For high-risk products such as dental implants and dental prostheses, we recommend consulting a local agent or consulting firm early to confirm the acceptance criteria for clinical evidence.

Applicability and Boundaries

Content Author: AIMEILI Regulatory Editorial Board. Professional Review: AIMEILI Medical Device International Registration Project Team. Source Principles: Official regulatory agencies, international organizations, standards bodies, and public regulatory materials are prioritized; industry media and project experience are used only as supplementary references. Applicability: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the official requirements of target country regulatory authorities, test conclusions, or legal opinions.